Medicine for the adsorption treatment of inflammatory diseases of the mucous membranes

 

(57) Abstract:

The invention relates to medicine, namely to the treatment of inflammatory diseases of the mucous membranes, such as the upper respiratory tract. The drug contains starch, agarose, preservative, including dioxidine and sulfalen meglumine, and saline, and optionally an acceptable target additives. The tool does not irritate the mucous membrane of the nose does not inhibit the transport function of ciliated epithelium, well removed and eliminates a large number of medicinal supplements. 3 C.p. f-crystals.

The invention relates to medicine, namely to the treatment of inflammatory diseases of the mucous membranes, such as the upper respiratory tract (otolaryngology) using adsorption therapy.

Known methods of treatment of diseases of the nose and paranasal ways in which the adsorbent is used hydrogel Aerosil (Y. I. Gladush, "To the question of sorption detoxification in introducing sinuitis" in kN. Proceedings of the regional scientific-practical conference of otolaryngologists extended Plenum PH OLO, Irkutsk, 1990, Medicine, S. 66-67/ or granular activated polednak proposed adsorbents, according to the authors, not physiological, but in our opinion, are simply the foreign body on the mucous membrane of the nasal cavity and paranasal sinuses and dramatically change the settings of the nasal mucus (viscosity, pH, cellular structure).

Closest to the invention by the combination of essential features is a medicinal mixture based on starch-agar gel (Markov, I. Differential diagnosis and methods of treatment of inflammatory diseases of the nose and paranasal sinuses. Abstract. dis. on competition of a scientific degree of doctor of honey. N. M., 1986, S. 24).

The drug mixture contains (wt. %): starch 0,1-0,2; agar-agar - 0,04-0,05; Supplement, various medications (diphenhydramine, ephedrine, mezaton and others), water, etc.

The disadvantage of this drug mixture is that it contains a large number of drugs multidirectional action. It requires an individual approach to its production. In addition, it in most cases is prepared on the water, which is not a physiological environment for the mucous membranes.

The invention is directed to the replacement of inorganic adsorbents and water on the physiological organic that allows to refuse from pain is achieved medicinal product for the adsorption treatment of inflammatory diseases of the mucous membranes, containing starch and agar is derived, which, as the agar is derived contains a agarose, and optionally, a preservative and a physiological solution in the following ratio, wt.%:

starch - 0.3 to 7

the agarose - 0,01-1

preservative - 0,01-5

saline - rest

As preservative medicinal product may contain dioxidine in an amount of 0.01-0.5 wt.% or sulfalen magmanet in an amount of 0.1-5 wt. %, as well as pharmaceutically acceptable additives target.

The difference of the medicinal product from the prototype is the increased starch content, the use of agarose and the introduction of additional preservative and saline solution. These differences provide collectively obtaining a medicinal product which has a viscosity and a pH close to those settings nasal mucus, does not irritate the mucous membrane does not inhibit the transport function of ciliated epithelium and is completely removed, has a long shelf life, can be prepared in pharmacies or as an official drug. Based on this tool, you can prepare a medicinal mixture symptomatic, pathogenetic and profilakticheskogo solution of 80 ml and 0.3 g of agarose to the boil and boiling the solution with constant stirring, add the mixture from 18,0-16,25 ml of physiological solution of 1.9 g of starch. The formed gel is cooled and introduced 0.1g dioxide or 1.85 g sulfalena of meglumine.

Received medication has a composition, wt.%6

starch - 1,9

the agarose - 0,3

dioxidine - 0,1

saline - rest

Similarly prepared medicinal product composition, wt.%:

starch - 2,5

the agarose - 0,5

sulfalen meglumine - 1,85

saline - rest

Clinical examples. Patient C. for 18 years, diagnosed with prolonged rhinitis. Ill 15 days. Complaints of nasal congestion, mucus. Took vasodilator drugs by instillation into the nose. Assigned drug dioksidin as preservative. On the 4th day from the start of treatment noted improvement, decreased nasal discharge, nasal breathing is restored.

Patient Z. 49 years, the diagnosis of atrophic rhinitis. Received 12 days instillation into the nose medicines with sulfalen meglumine 5 drops 3 times a day. The patient noted significant subjective improvement - nasal breathing is restored, no dryness, no crusts.

Patient K. 30 years, the diagnosis - acute inosinic. Complaints hall is the adding of sosudorasshiryayuschee drug mezaton in the form of a 0.1% solution. Traditional instillation into the nose 5 drops 3 times a day. This allowed for a 4 day to improve the patient's condition. From the first day of use, the patient reported improvement of nasal breathing, a significant decrease in headaches; on the 3rd day was sharply reduced nasal discharge. On day 4 the patient has not filed any complaints. When examining the mucous membrane of the nasal Concha some redness, nasal passages free, nasal breathing is not impeded. On the 8th day if diaphanoscopy apparatus UMP reduction of scanning of the sinuses is not defined.

Thus, the introduction of the adsorbent in the form of starch gel with agarose and preservative physiological solution having a rapid effect on the removal of the products of inflammation from the mucous membranes, restores the function of the nose and ensures its correct reflex action.

It should be said that with increasing concentration of starch and agarose viscosity medicines increases, but it can be used by introducing into the nasal cavity as an ointment form.

1. Medicine for the adsorption treatment of inflammatory diseases of the mucous membranes, containing starch and agar production is NT and saline solution in the following ratio of components, wt.%:

Starch - 0.3 to 7

The agarose - 0,01 - 1

Preservative - 0,01 - 5

Saline - Rest

2. Drug under item 1, characterized in that as preservatives it contains dioxidine in the following ratio, wt.%:

Starch - 0.3 to 7

The agarose - 0,01 - 1

Dioxidine - 0,01 - 0,5

Saline - Rest

3. Drug under item 1, characterized in that as preservatives it contains sulfalen meglumine in the following ratio, wt.%:

Starch - 0.3 to 7

The agarose - 0,01 - 1

Sulfalen meglumine - 0,1 - 5

Saline - Rest

4. The drug according to any one of paragraphs.1 to 3, characterized in that it includes the additional pharmaceutically acceptable additives target.

 

Same patents:

d-arabinofuranosyl)-n-purine, method for their preparation and use and pharmaceutical composition" target="_blank">

The invention relates to mono-, di - or tri-esters of 2-amino-6-(C1-C5-alkoxy)-9-(-D-arabinofuranosyl)-N-purine General formula (I)

< / BR>
where arabinofuranosyl residue substituted for 2'-, 3'- or 5'-positions, and esters formed by carboxylic acids, in which decarbonising part selected from n-propyl, tert-butyl, n-butyl, methoxymethyl, benzyl, phenoxymethyl, phenyl, methanesulfonyl and succinyl
The invention relates to medicine, namely the subject of the invention are tablets based on partially or fully water-soluble natural and/or synthetic polymers selected from rubbers, alginates, Cartagena, starch, pectin and gelatin containing poly-(dimethyl-siloxanes) (Dimethicone, simethicone), and the method of their manufacture
The invention relates to medicine, in particular to methods for treating obesity

The invention relates to oligonucleotides and their derivatives to suppress the expression of isoprenylation, pharmaceutical compositions containing such compounds and to the use of such compositions of oligonucleotides for the treatment or therapy of the human or animal diseases caused by abnormal and/or unregulated proliferation

d-arabinofuranosyl-2-amino-6-methoxy - n-purines" target="_blank">

The invention relates to 9--D-arabinofuranosyl-2-amino-6-methoxy-N-purine and its derivatives and 9--D-arabinofuranosyl-2-amino-6-methoxy-N-purine and its derivatives and pharmaceutical compositions comprising these derivatives of purine, which is active against viral infections in humans caused by the virus stays zoster (VZV)

The invention relates to a substance which can be used for a new purpose, namely as a drug against HIV-1

The invention relates to medicine, in particular to Oncology and for the correction of the depression of hematopoiesis due to chemoradiation therapy

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

FIELD: medicine, obstetrics, gynecology.

SUBSTANCE: at the background of therapy conducted one should introduce derinate immunomodulator into the body of pregnant woman additionally nasally per 1-2 drops of 0.25%-solution into each nasal canal 5-8 times daily for 3-5 d and - parenterally per 5.0 ml of 1.5%-solution once daily for 3-8 d along with preparation that improves microcirculation and along with antioxidant at a certain sequence, moreover, derinate should be introduced 30-40 min after application of microcirculation-improving preparation, and antioxidant - 20-30 min after derinate's introduction. The present innovation favors decreased edemas, decreased body weight, stabilization of Macluer-Aldrich test that in its turn enables to avoid perinatal losses, decrease the risk for the development of fetoplacental insufficiency and intrauterine fetal infection.

EFFECT: higher efficiency of therapy.

1 ex, 2 tbl

FIELD: medicine, otolaryngology.

SUBSTANCE: the present innovation deals with introducing neomycin sulfate antibiotic in granules prepared by the following technique. Tablet of neomycin sulfate 1.0g should be put into a vial with 100 ml distilled water till tablet's decomposition. Then vial's content should be shaken and kept till suspension sedimentation. In a day one should take 1 ml of supernatant liquid to be put into another vial and diluted with distilled water at 1:100 ratio. This procedure should be repeated 4 times more, moreover, during the last procedure one should apply alcohol for dilution. Then one should transfer the drop of alcoholic solution into a vial with granules out of milk sugar to then shaken and kept open for 1 d till granules" drying up. The suggested preparation should be applied per 1 granule under the tongue, moreover, multiplicity and duration of the above-suggested intake should be matched individually by patient's sensitivity and obtaining the clinic effect. The method enables to improve the value of tonic threshold audiometry by about 30-50 dB, decrease perception threshold of vocal range frequencies and widen the range towards high frequencies.

EFFECT: higher efficiency of therapy.

1 dwg

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of chronic lympholeukosis. Method involves intravenous drop and jet administration of antitumor chemopreparations and carrying out the autochemotherapy. At the 1-st and 8-th day of treatment cyclophosphan in the dose 750 mg/m2, vincristine in the dose 1.4 mg/m2 and doxorubicin in the dose 30 mg/m2 incubated with 200 ml of autoblood are administrated to patients. From the 1-st to 14-th day of treatment prednisolone is used every day in the therapeutic dose. The treatment course is repeated in 30-35 days depending on blood indices and patient state. The total treatment of courses is 4-5. Method provides reducing cardiotoxicity of doxorubicin and cumulative toxicity of chemopreparations that allows carrying out administration of antitumor chemopreparations in the full volume to patients of elderly age groups.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, oncohematology.

SUBSTANCE: the present innovation deals with treating elderly patients with chronic lympholeukosis accompanied with cardiovascular failure. The method deals with applying chemopreparations and cytoprotector. Moreover, 1 wk before the onset of chemotherapeutic therapy one should prescribe preductal at the dosage of 105 mg daily. At this background one should sample blood out of elbow vein at the volume of 200 ml into a vial with glugicir to centrifuge it, isolate plasma, divide into two portions, add into the 1st vial - cyclophosphan 600-800 mg/sq. m, vincristin 1.4 mg/sq. m, into the 2nd vial - adriamycin 50 mg/sq. m to be incubated for 30 min at 37 C and intravenously injected by drops for patients. Simultaneously, the intake of prednisolone should be prescribed at the dosage of 60 mg/sq. m since the 1st d and during the next 5 d and preductal at the dosage of 105 mg daily during a week, and then 2 wk more at the dosage of 60 mg daily. All the procedures should be repeated in above-mentioned sequence 4-6 times. The method enables to decrease toxic manifestations of chemotherapy while applying adequate dosages of cytostatics, anthracycline antibiotics, among them, at no great manifestations of their toxicity due to preductal's cardioprotective action.

EFFECT: higher efficiency of therapy.

1 ex, 5 tbl

FIELD: medicine, immunology, nucleic acids.

SUBSTANCE: invention relates to a method for stimulation of the immune response using nucleic acids-containing immunostimulating compositions, oligonucleotide-containing composition and to a method for treatment or prophylaxis of allergy or asthma. For stimulation of the immune response thymidine-enriched nucleic acid comprising poly-T sequences and/or comprising above 60% of thymidine-containing nucleotide residues is administrated. Invention provides the development of new method for stimulation of the immune response due to administration of the proposed immunostimulating nucleic acid.

EFFECT: valuable medicinal properties of nucleic acid.

27 cl, 12 dwg, 12 ex

FIELD: veterinary science.

SUBSTANCE: the suggested method should be performed under conditions of experimental modeling dystrophic process due to intraosseous introduction of glucosamine hydrochloride at the dosage of 15-25 mg/kg 1-2 times weekly during a month. The method provides high local concentrations of medicinal preparation, at its steady entering the circulation by leaving aside hepatic barrier and, as a result, optimization of chondroprotector action of glucosamine hydrochloride and better treatment of articular alterations induced in the course of an experiment in animals.

EFFECT: higher efficiency of correction.

8 dwg, 1 ex

FIELD: veterinary science.

SUBSTANCE: the suggested method should be implemented under conditions of experimental modeling dystrophic process due to intramuscular injection of glucosamine hydrochloride at the dosage of 15-25 mg/kg once or twice weekly for 1 mo. The method provides good effect in treating a lesion induced in the course of an experiment due to matching adequate dosages and a certain mode of injecting chondroprotector in animals.

EFFECT: higher efficiency of correction.

6 dwg

FIELD: medicine, neurology.

SUBSTANCE: method involves intravenous administration of autolymphocytes treated with an immunomodulating agent by extracorporal method using cycloferon (250 mg) as an immunomodulating agent. Simultaneously, the following medicinal mixture comprising lidocaine, 100 mg; lidazum, 32 U; dexamethasone, 4 mg; leukinferon, 10 000 U; 40% glucose solution, 4 ml is administrated into interspinal ligaments of spinal column at levels corresponding to thoracal and lumbar enlargements of the spinal cord. The procedure is repeated three times with interval for 48-72 h. Method provides enhancing the effectiveness of lymphostimulation and immunomodulation in cerebrospinal sclerosis. Invention can be used for lymphostimulation and immunomodulation in cerebrospinal sclerosis.

EFFECT: improved method for treatment.

1 tbl, 1 ex

FIELD: medicine, pulmonology.

SUBSTANCE: one should apply lycopid to study initial level of mature T-cells (CD3+) in % and solve following discriminant equation: D = 0.840 · (CD3+), and at D value being above 29.24 one should predict positive curative effect as a result of lycopid application, and at D value being below 29.24 on should predict no positive curative effect.

EFFECT: higher efficiency of lycopid-including therapy.

2 ex

Up!